Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants

Compass Therapeutics, Inc.

Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.
Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.
Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.
Cash and equivalents expected to fund operations into 2028.
Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.